NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Current Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
---|---|---|---|---|---|
Total Current Liabilities | ₹365 Cr | ₹262 Cr | ₹216 Cr | ₹194 Cr | ₹98 Cr |
What is the latest Total Current Liabilities ratio of NATH BIOGENES (INDIA) ?
Year | Total Current Liabilities |
---|---|
Mar2025 | ₹365 Cr |
Mar2024 | ₹262 Cr |
Mar2023 | ₹216 Cr |
Mar2022 | ₹194 Cr |
Mar2013 | ₹98 Cr |
How is Total Current Liabilities of NATH BIOGENES (INDIA) Trending?
Years | Total Current Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹365 Cr | 39.19 | |
Mar2024 | ₹262 Cr | 21.26 | |
Mar2023 | ₹216 Cr | 11.40 | |
Mar2022 | ₹194 Cr | 98.02 | |
Mar2013 | ₹98 Cr | - |
Compare Total Current Liabilities of peers of NATH BIOGENES (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATH BIOGENES (INDIA) | ₹314.3 Cr | -3.1% | -7.1% | -24.6% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹13,507.8 Cr | -1.2% | 3.7% | -28.8% | Stock Analytics | |
KAVERI SEED COMPANY | ₹6,090.6 Cr | 2.8% | 8.9% | 9.7% | Stock Analytics | |
VENKYS (INDIA) | ₹2,143.8 Cr | 1.7% | 6.9% | -33.4% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,365.6 Cr | -3.8% | -2.4% | -30.1% | Stock Analytics | |
INDO US BIOTECH | ₹288.1 Cr | -0.4% | -5.2% | -56.8% | Stock Analytics |
NATH BIOGENES (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATH BIOGENES (INDIA) | -3.1% |
-7.1% |
-24.6% |
SENSEX | 0.9% |
1.2% |
-0.4% |
You may also like the below Video Courses